Loading…
SYNTOMETRINE is a brand name for Oxytocin. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: The active management of the third stage of labour (as a means to promote separation of the placenta and to reduce blood loss), or routinely, following the birth of the placenta, to prevent or treat postpartum haemorrhage.
Verbatim from this product's MHRA label. Tap a section to expand.
Syntometrine should be used under medical supervision only.
Adults:
Active management of third stage of labour: Intramuscular injection of 1ml after delivery of the anterior shoulder, or at the latest, immediately after delivery of the child. Expulsion of the placenta, which is normally separated by the first strong uterine contraction, should be assisted by controlled cord traction.
Prevention and treatment of postpartum haemorrhage:
Intramuscular injection of 1ml following expulsion of the placenta, or when bleeding occurs. Special populations Renal impairment / Hepatic impairment No studies have been performed in patients with renal or hepatic impairment. However considering the metabolic pathway of ergometrine and oxytocin, use is contraindicated in severe hepatic and renal impairment and caution is required in mild or moderate hepatic and renal impairment (see sections
). 8 Undesirable effects The following adverse drug reactions have been reported during post-approval use of Syntometrine via spontaneous case reports and literature cases. Because these reactions are reported voluntarily from a population of uncertain size and subject to confounding factors, it is not possible to reliably estimate their frequency which is therefore quoted as not known.
Adverse drug reactions are listed according to system organ classes in MedDRA. Within each system class organ class, ADRs are presented in order of decreasing seriousness. 4 Special warnings and precautions for use) bradycardia, cardiac arrhythmias, chest pain Vascular disorders hypertension Gastrointestinal disorders vomiting, nausea, abdominal pain Skin and subcutaneous tissue disorders Rash, angioedema Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow card in the Google Play or Apple App Store.
2 Pharmacokinetic properties).
Paediatric population:
No data are available.
Elderly:
Not applicable. Method of administration Intramuscular injection is the recommended route. 5 to 1 mL by slow injection) is possible, but should be limited to use only in cases of severe haemorrhage due to uterine atony. 1. • Pregnancy and labour (induction of labour, first stage labour and second stage labour prior to the delivery of the anterior shoulder) due to the risk of uterine hypertonus and associated foetal complications (see section
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Oxytocin in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.